Shares of Rhythm Pharmaceuticals Inc. (RYTM) tumbled 5.65% in pre-market trading on Wednesday, following a notable downgrade from a key analyst. The biopharmaceutical company, which focuses on developing therapies for rare genetic disorders of obesity, saw its stock price significantly impacted by the change in analyst sentiment.

The primary catalyst for the sharp decline appears to be Oppenheimer's decision to downgrade Rhythm Pharmaceuticals. The firm lowered its rating on RYTM from Outperform to Perform, effectively changing its recommendation from a Buy to a Hold. This adjustment in outlook from a respected financial services company likely prompted investors to reassess their positions, leading to the observed sell-off.

While the exact reasons behind Oppenheimer's downgrade were not immediately clear, such changes in analyst ratings often reflect concerns about a company's near-term prospects or valuation. The market's strong negative reaction suggests that investors are taking this downgrade seriously, potentially reassessing Rhythm Pharmaceuticals' growth prospects or market position in the competitive biotech sector.